In The Spotlight: ZIOPHARM Oncology
5/24/2010 2:07 PM ET


(RTTNews) - Why it is profiled?
The company will be presenting additional data for its investigational drug Palifosfamide (ZIO-201) from a mid-stage sarcoma trial.

ZIOPHARM Oncology Inc. (ZIOP: News ) is a biopharmaceutical companyfocused on the development and commercialization of small molecule cancer drugs. The shares of this development-stage company have gained nearly 97% year-to-date and trade over $5.50.

More in

In The Spotlight: ZIOPHARM Oncology